购物车
- 全部删除
- 您的购物车当前为空
KU-0060648 是一种 PI3K 和 DNA-PK 的双重抑制剂,对 PI3Kα、PI3Kβ、PI3Kδ、PI3Kγ 和 DNA-PK 的 IC50值分别为 4 nM、0.5 nM、0.1 nM、0.59 nM 和 8.6 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
KU-0060648 是一种 PI3K 和 DNA-PK 的双重抑制剂,对 PI3Kα、PI3Kβ、PI3Kδ、PI3Kγ 和 DNA-PK 的 IC50值分别为 4 nM、0.5 nM、0.1 nM、0.59 nM 和 8.6 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 472 | 现货 | |
5 mg | ¥ 1,070 | 现货 | |
10 mg | ¥ 1,730 | 现货 | |
25 mg | ¥ 3,150 | 现货 | |
50 mg | ¥ 4,520 | 现货 | |
100 mg | ¥ 6,350 | 现货 |
产品描述 | KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM. |
靶点活性 | PI3Kα:4 nM, PI3Kδ:0.1 nM, PI3Kβ:0.5 nM |
体外活性 | KU-0060648 exhibits differential effects on growth inhibition, but is not profoundly cytotoxic in a panel of human cancer cell lines. It inhibits DNA-PK and PI-3K with greater potency in MCF7 than SW620 cell using cell-based assays. Five-day exposure to 1 mM KU-0060648 inhibits cell proliferation by more than 95% in MCF7 cells but only by 55% in SW620 cells. In clonogenic survival assays, KU-0060648 increases the cytotoxicity of etoposide and doxorubicin across the panel of DNA-PKcs-proficient cells, but not in DNA-PKcs-deficient cells, confirming that enhanced cytotoxicity of the topoisomerase II poisons etoposide and doxorubicin is due to DNA-PK inhibition. [1] |
体内活性 | KU-0060648 enhances the anti-tumour activity of etoposide in both MCF7 and SW620 xenograft models, and has single-agent activity in the MCF7 xenograft model. [1] |
细胞实验 | SRB assay(Only for Reference) |
别名 | KU0060648 |
分子量 | 582.71 |
分子式 | C33H34N4O4S |
CAS No. | 881375-00-4 |
Smiles | CCN1CCN(CC(=O)Nc2ccc(-c3cccc4c3oc(cc4=O)N3CCOCC3)c3sc4ccccc4c23)CC1 |
密度 | 1.337 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | 2eq.HCl: 58.3 mg/mL (100 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容